
Arcellx (ACLX) Stock Forecast & Price Target
Arcellx (ACLX) Analyst Ratings
Bulls say
Arcellx Inc. is positioned favorably due to its collaboration with Gilead, leveraging KITE cell therapy manufacturing and patient support that is expected to enhance commercial viability and market access for its therapies. The robust clinical profile of Anito-cel, which shows comparable durability to existing CAR-T therapies, underscores its potential for significant market success, particularly with projected approval in multiple myeloma patients by the end of 2026. With an estimated $7 billion in peak global sales driven by anticipated label expansions, the company is on a solid trajectory toward achieving profitability, backed by strong management execution in developing transformative immunotherapies.
Bears say
Arcellx Inc faces significant challenges that contribute to a negative outlook, including the uncertainty surrounding the successful development of its D-Domain CAR-T therapy platform and ARC-SparX platform for generating viable clinical candidates. The company's implied equity value of $7.8 billion hinges on the completion of its acquisition by GILD, which introduces substantial commercial and regulatory risks, as well as potential dilution from future financing. Additionally, competitive pressures and the possibility of underwhelming product profiles further exacerbate the inherent risks to Arcellx's valuation and stock performance.
This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.
Arcellx (ACLX) Analyst Forecast & Price Prediction
Start investing in Arcellx (ACLX)
Order type
Buy in
Order amount
Est. shares
0 shares